Leuprolide

Mechanism

One of the most widely prescribed GnRH agonists. Like triptorelin, it initially stimulates testosterone/estrogen then suppresses them with continued use. FDA-approved for prostate cancer, endometriosis, uterine fibroids, precocious puberty, and as part of IVF protocols. Available in depot forms lasting 1, 3, 4, or 6 months.

Effects

**Endocrine — HPG Axis (Tier 1 — Human Clinical):** Leuprolide is a GnRH superagonist that causes initial pituitary stimulation (LH/FSH surge and testosterone/estrogen flare for 1–2 weeks) followed by receptor desensitization/downregulation and profound hypogonadism. Castrate testosterone levels (<50 ng/dL) achieved within 2–4 weeks. The most widely prescribed GnRH agonist worldwide. **Reproductive — Male (Tier 1 — Human Clinical):** Standard androgen deprivation therapy for prostate cancer. Also used for chemical castration in sex offender management (legal/forensic context). Suppresses spermatogenesis — azoospermia in most men by 3–6 months. **Reproductive — Female (Tier 1 — Human Clinical):** Creates reversible medical menopause. Used for endometriosis, uterine fibroids (pre-operative shrinkage), central precocious puberty (in children), and IVF pituitary downregulation. **Musculoskeletal (Tier 1 — Side Effect):** Significant bone loss during treatment: 3–7% BMD reduction per year in women, 2–5% in men. In children treated for precocious puberty, bone age progression slows appropriately. BMD generally recovers after discontinuation in premenopausal women and children. **Neuropsychiatric (Tier 2 — Clinical Observation):** Depression, mood changes, and cognitive effects ("chemo brain") reported by patients on long-term leuprolide. Estrogen deprivation in women and testosterone deprivation in men both affect mood, cognition, and quality of life. FDA mandated labeling changes in 2017 regarding depression and suicidal ideation risk. **Metabolic (Tier 1 — Side Effect):** Metabolic syndrome: weight gain, insulin resistance, dyslipidemia, increased waist circumference. Increased cardiovascular risk, particularly in men on long-term ADT.

Practitioner Guide

**APPROVED INDICATIONS:** • Advanced prostate cancer (ADT). • Endometriosis. • Uterine fibroids (pre-operative). • Central precocious puberty. • IVF (pituitary downregulation). **DOSING:** • Monthly: 7.5 mg IM or SC every month (Lupron Depot). • 3-month: 22.5 mg IM every 3 months. • 4-month: 30 mg IM every 4 months. • 6-month: 45 mg IM every 6 months. • Pediatric (precocious puberty): Weight-based dosing, typically starting at 7.5–15 mg monthly. **FLARE MANAGEMENT (Same Principles as Goserelin):** • Anti-androgen cover (bicalutamide 50 mg daily) started 1–2 weeks before first leuprolide injection and continued for 2–4 weeks. • High-risk patients (symptomatic mets, cord compression): Use degarelix instead to avoid flare entirely. • Post-first-dose flare monitoring: Watch for bone pain, urinary retention, neurological symptoms in men with known metastatic disease. Admit if high-risk. **BONE DENSITY MONITORING — LONG-TERM USE:** • Same DEXA protocol as goserelin: baseline and every 1–2 years. • Bone protection: Calcium 1200 mg/day, vitamin D 1000–2000 IU/day. Bisphosphonate or denosumab for established osteopenia/osteoporosis. • In women: Limit treatment to 6 months without add-back therapy. • In children with precocious puberty: BMD monitoring during treatment. Recovery expected after discontinuation at appropriate age. **ADD-BACK THERAPY FOR WOMEN (Same Principles as Goserelin):** • Norethindrone acetate 5 mg daily is the standard add-back regimen for endometriosis treatment beyond 6 months. • Start add-back from Day 1 — no evidence supports delayed initiation. • Add-back reduces hot flashes by ~50–70% and prevents significant bone loss while maintaining endometriosis treatment efficacy. **THE TRIPTORELIN PCT PHENOMENON — DETAILED ANALYSIS:** • Origin: A 2010 case report described a bodybuilder on anabolic steroids who received a single 100 mcg dose of triptorelin (a GnRH agonist similar to leuprolide) and reportedly experienced rapid restoration of testosterone production. This led to viral adoption of "triptorelin PCT" in bodybuilding forums. • The claimed mechanism: A single small dose of GnRH agonist triggers a massive LH surge that "jumpstarts" the suppressed HPTA (hypothalamic-pituitary-testicular axis) after steroid cycling. • Why this is problematic: (1) The initial LH/FSH surge from a GnRH agonist is FOLLOWED by receptor downregulation and suppression. Even a single dose can cause weeks of suppression if the dose exceeds the stimulatory threshold. (2) 100 mcg of triptorelin is NOT a micro-dose — therapeutic triptorelin doses for prostate cancer start at 3.75 mg monthly, but even 100 mcg can cause significant pituitary effects. (3) There are documented cases of prolonged hypogonadism (months) after single-dose triptorelin in bodybuilders. This represents iatrogenic castration. (4) Individual variation in GnRH receptor sensitivity means the same dose can produce different outcomes — some may get the desired LH surge, others may get prolonged suppression. • Clinical pearl: If a patient asks about triptorelin PCT, counsel firmly against it. Standard PCT protocols (clomiphene 50 mg/day for 4–6 weeks, or tamoxifen 20–40 mg/day for 4–6 weeks, with or without hCG priming) are evidence-based and dose-titratable. GnRH agonist PCT is a pharmacological gamble with potentially devastating consequences. • Note: Leuprolide (Lupron) is sometimes mentioned in the same context as triptorelin for PCT. The same warnings apply — NO GnRH agonist should be used for post-cycle therapy.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  Leuprolide is teratogenic. Causes fetal harm via disruption of hormonal environment. Labeled contraindication per Lupron prescribing information.
  Action: Absolutely contraindicated. Do not use during pregnancy. Verify negative pregnancy test.
• hard stop — Breastfeeding
  GnRH agonist suppresses hormones required for lactation.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GnRH agonist. Not for unsupervised use in minors. (Note: has specific pediatric indications under specialist care.)
  Action: Do not provide outside of specialist pediatric care.
• requires physician — Osteoporosis
  Long-term GnRH agonist use causes bone mineral density loss due to sex hormone suppression. Labeled warning per Lupron prescribing information.
  Action: Requires DEXA scan before initiation. Consider bone-protective co-therapy. Monitor BMD.
• monitor — Depression or mood disorders
  Sex hormone suppression worsens mood and may precipitate depression. Depression and suicidal ideation reported in post-marketing surveillance.
  Action: Monitor mood closely. Psychiatric evaluation recommended.
• requires physician — Cardiovascular disease
  Androgen deprivation therapy increases cardiovascular risk per FDA safety communication. Associated with MI, stroke, and sudden death.
  Action: Requires cardiovascular evaluation. Monitor lipids, BP, and glucose. Cardiology consultation for existing CVD.
• requires physician — Diabetes
  GnRH agonist-induced hypogonadism may worsen insulin resistance and glycemic control. Labeled warning for hyperglycemia.
  Action: Monitor blood glucose. Diabetes medication adjustment may be needed.

Evidence

• Clinical pharmacology of leuprolide

  Periti P, Mazzei T, Mini E (2002) — Clinical Pharmacokinetics

  Leuprolide acetate (Lupron) is one of the most widely prescribed GnRH agonists with FDA approval for prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and IVF. Depot formulations provide sustained release over 1-6 months. Mechanism involves initial gonadotropin flare followed by receptor downregulation and sex steroid suppression. Decades of safety data support long-term use.

  strong

• Leuprolide versus diethylstilbestrol for metastatic prostate cancer

  Leuprolide Study Group (1984) — New England Journal of Medicine — PMID: 6417948

  Leuprolide acetate was equivalent to diethylstilbestrol (DES) for treatment of metastatic prostate cancer in a multicenter RCT, with comparable survival and disease response rates. Leuprolide had significantly fewer cardiovascular side effects than DES (no gynecomastia, thromboembolic events). Established medical castration with GnRH agonists as standard of care, replacing surgical orchiectomy and DES.

  strong

Research Summary

**Tier 1 (Human Clinical Evidence):** • Prostate cancer: Decades of Phase III data. Lupron is the most extensively studied GnRH agonist. Non-inferior to orchiectomy. Multiple formulations provide flexible dosing. • Endometriosis: Cochrane review confirms significant pain reduction. Limited to 6 months without add-back. • Central precocious puberty: Standard of care since the 1980s. Effectively halts puberty progression and allows age-appropriate resumption after discontinuation. • Uterine fibroids: Significant fibroid volume reduction (30–65%) within 3–6 months. Used primarily as bridge to surgery. **Tier 2 (Strong Preclinical + Mechanistic):** • GnRH receptor desensitization mechanism thoroughly characterized — receptor internalization, downregulation of mRNA, and pituitary gonadotroph desensitization. • Long-acting depot formulations use PLGA microsphere technology — well-understood drug delivery system. **Tier 3 (Emerging / Theoretical):** • Oral GnRH antagonists (relugolix) may eventually replace leuprolide for many indications due to convenience and potentially better cardiovascular profile. • Neuropsychiatric effects warrant further study — proposed mechanisms include direct neuronal GnRH receptor effects and secondary effects of sex steroid deprivation.